Division of Cardiology, Department of Medicine, Weill Cornell Medical College, New York, USA.
Curr Atheroscler Rep. 2011 Aug;13(4):290-7. doi: 10.1007/s11883-011-0188-x.
Atrial fibrillation (AF) is a large public health problem that affects about 1% of the population in the United States. It confers an increased risk for stroke and thromboembolism, but the stroke risk is not equal in all patients. Further refinement in stratifying stroke risk in patients with AF will help in properly directing therapy for AF patients while minimizing adverse events. Warfarin is the first-line treatment for stroke reduction in patients with AF, but many new drugs are on the horizon that will significantly change practice. New and improved cardiac monitoring techniques and devices will help with detection of AF in those at risk for stroke and will assist in assessing which patients will most benefit from anticoagulation.
心房颤动（AF）是一个重大的公共卫生问题，影响了大约 1%的美国人口。它增加了中风和血栓栓塞的风险，但并非所有患者的中风风险都相同。进一步细化 AF 患者的中风风险分层将有助于为 AF 患者提供适当的治疗，同时最大限度地减少不良事件。华法林是 AF 患者降低中风风险的一线治疗药物，但许多新药物即将面世，这将显著改变实践。新的和改进的心脏监测技术和设备将有助于检测有中风风险的患者的 AF，并有助于评估哪些患者最受益于抗凝治疗。
